{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:13:20Z","timestamp":1791357200602,"version":"4.3.1"},"reference-count":27,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T00:00:00Z","timestamp":1346457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T00:00:00Z","timestamp":1346457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy Research"],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1016\/j.eplepsyres.2012.04.001","type":"journal-article","created":{"date-parts":[[2012,4,28]],"date-time":"2012-04-28T16:28:20Z","timestamp":1335630500000},"page":"202-209","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":49,"title":["Risk factors for hyperammonemia associated with valproic acid therapy in adult epilepsy patients"],"prefix":"10.1016","volume":"101","author":[{"given":"Yoshiaki","family":"Yamamoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukitoshi","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eri","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyuki","family":"Mishima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuyuki","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunihiko","family":"Itoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiyuki","family":"Kagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yushi","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eplepsyres.2012.04.001_bib0005","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1177\/088307389701200709","article-title":"Asymptomatic hyperammonemia in children treated with valproic acid","volume":"12","author":"Altunba\u015fak","year":"1997","journal-title":"J. Child Neurol."},{"key":"10.1016\/j.eplepsyres.2012.04.001_bib0010","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.jhep.2010.11.031","article-title":"New insights on the mechanisms of valproate-induced hyperammonemia: inhibition of hepatic N-acetylglutamate synthase activity by valproyl-CoA","volume":"55","author":"Aires","year":"2011","journal-title":"J. Hepatol."},{"key":"10.1016\/j.eplepsyres.2012.04.001_bib0015","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.brainresrev.2007.06.026","article-title":"Hyperammonemia-induced toxicity for the developing central nervous system","volume":"56","author":"Cagnon","year":"2007","journal-title":"Brain Res. Rev."},{"key":"10.1016\/j.eplepsyres.2012.04.001_bib0020","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1097\/chi.0b013e31802ed8b2","article-title":"Case report: valproic Acid and risperidone treatment leading to development of hyperammonemia and mania","volume":"46","author":"Carlson","year":"2007","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"key":"10.1016\/j.eplepsyres.2012.04.001_bib0025","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.yebeh.2007.06.015","article-title":"The measurement of ammonia blood levels in patients taking valproic acid: looking for problems where they do not exist?","volume":"11","author":"Chicharro","year":"2007","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.eplepsyres.2012.04.001_bib0030","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1097\/WNF.0b013e3181ac3615","article-title":"Valproate-induced hyperammonemic encephalopathy and normal liver functions: possible synergism with topiramate","volume":"32","author":"Deutsch","year":"2009","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.eplepsyres.2012.04.001_bib0035","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1097\/00007691-198507030-00009","article-title":"Chronic valproic acid therapy and incidence of increases in venous plasma ammonia","volume":"7","author":"Haidukewych","year":"1985","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.eplepsyres.2012.04.001_bib0040","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1212\/WNL.54.1.230","article-title":"Valproate-induced hyperammonemic encephalopathy in the presence of topiramate","volume":"54","author":"Hamer","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.eplepsyres.2012.04.001_bib0045","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.eplepsyres.2009.04.002","article-title":"The risk of asymptomatic hyperammonemia in children with idiopathic epilepsy treated with valproate: relationship to blood carnitine status","volume":"86","author":"Hamed","year":"2009","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2012.04.001_bib0050","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1111\/j.1528-1167.2011.03279.x","article-title":"Transient hyperammonemia in seizures: a prospective study","volume":"52","author":"Hung","year":"2011","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2012.04.001_bib0055","doi-asserted-by":"crossref","first-page":"700","DOI":"10.2169\/internalmedicine.37.700","article-title":"Fatal hyperammonemia in a patient with systemic lupus erythematosus","volume":"37","author":"Ichikawa","year":"1998","journal-title":"Intern. Med."},{"key":"10.1016\/j.eplepsyres.2012.04.001_bib0060","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1136\/jnnp.2006.105353","article-title":"Aggravation of ataxia due to acetazolamide induced hyperammonaemia in episodic ataxia","volume":"78","author":"Kim","year":"2007","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.eplepsyres.2012.04.001_bib0065","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/j.1365-2710.2008.00943.x","article-title":"Adjunctive topiramate enhances the risk of hypothermia associated with valproic acid therapy","volume":"33","author":"Knudsen","year":"2008","journal-title":"J. Clin. Pharm. Ther."},{"key":"10.1016\/j.eplepsyres.2012.04.001_bib0070","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1111\/j.1528-1157.1992.tb01708.x","article-title":"Is 2-propyl-4-pentenoic acid, a hepatotoxic metabolite of valproate, responsible for valproate-induced hyperammonemia?","volume":"33","author":"Kondo","year":"1992","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2012.04.001_bib0075","first-page":"663","article-title":"Blood ammonia level during valproic acid therapy","volume":"40","author":"Kugoh","year":"1986","journal-title":"Jpn. J. Psychiatry Neurol."},{"key":"10.1016\/j.eplepsyres.2012.04.001_bib0080","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1528-1157.1986.tb03501.x","article-title":"Nutritional influence on serum ammonia in young patients receiving sodium valproate","volume":"27","author":"Laub","year":"1986","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2012.04.001_bib0085","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1007\/s10545-008-0834-9","article-title":"Profiling of astrocyte properties in the hyperammonaemic brain: shedding new light on the pathophysiology of the brain damage in hyperammonaemia","volume":"31","author":"Lichter-Konecki","year":"2008","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.eplepsyres.2012.04.001_bib0090","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1046\/j.1528-1157.2002.42401.x","article-title":"Topiramate enhances the risk of valproate-associated side effects in three children","volume":"43","author":"Longin","year":"2002","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2012.04.001_bib0095","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1046\/j.1528-1157.2002.13001.x","article-title":"The importance of drug interactions in epilepsy therapy","volume":"43","author":"Patsalos","year":"2002","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2012.04.001_bib0100","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/j.1528-1167.2008.01561.x","article-title":"Antiepileptic drugs \u2013 best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring. ILAE Commission on Therapeutic Strategies","volume":"49","author":"Patsalos","year":"2008","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2012.04.001_bib0105","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1345\/aph.19242","article-title":"The role of carnitine supplementation during valproic acid therapy","volume":"34","author":"Raskind","year":"2000","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.eplepsyres.2012.04.001_bib0110","first-page":"100","article-title":"Hyperammonaemia and hepatotoxicity during chronic valproate therapy: enhancement by combination with other antiepileptic drugs","volume":"22","author":"Ratnaike","year":"1986","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.eplepsyres.2012.04.001_bib0115","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1600-0404.1992.tb05085.x","article-title":"Carbamyl phosphate synthetase-1 deficiency discovered after valproic acid-induced coma","volume":"86","author":"Verbiest","year":"1992","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.eplepsyres.2012.04.001_bib0120","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s005990050060","article-title":"Carnitine deficiency and hyperammonemia in children receiving valproic acid with and without other anticonvulsant drugs","volume":"29","author":"Verrotti","year":"1999","journal-title":"Int. J. Clin. Lab. Res."},{"key":"10.1016\/j.eplepsyres.2012.04.001_bib0125","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1212\/WNL.34.11.1487","article-title":"Increase of valproate-induced hyperammonemia in normal subjects by carbohydrate intake","volume":"34","author":"Warter","year":"1984","journal-title":"Neurology"},{"key":"10.1016\/j.eplepsyres.2012.04.001_bib0130","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1212\/WNL.34.4.550","article-title":"Valproic acid-induced hyperammonemia in mentally retarded adults","volume":"34","author":"Williams","year":"1984","journal-title":"Neurology"},{"key":"10.1016\/j.eplepsyres.2012.04.001_bib0135","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1111\/j.1442-200X.2010.03157.x","article-title":"Effect of CPS14217C>A genotype on valproic-acid-induced hyperammonemia","volume":"52","author":"Yagi","year":"2010","journal-title":"Pediatr. Int."}],"container-title":["Epilepsy Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121112000964?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121112000964?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T13:27:37Z","timestamp":1760275657000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920121112000964"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["S0920121112000964"],"URL":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2012.04.001","relation":{},"ISSN":["0920-1211"],"issn-type":[{"value":"0920-1211","type":"print"}],"subject":[],"published":{"date-parts":[[2012,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk factors for hyperammonemia associated with valproic acid therapy in adult epilepsy patients","name":"articletitle","label":"Article Title"},{"value":"Epilepsy Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2012.04.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}